Annual US spending on oral cancer drugs has surpassed $947 million and is expected to increase 12% to 15% annually through 2027. In many cases, a significant portion of these funds come directly from patients. The out-of-pocket costs for the top 54 oral chemotherapy agents in 2019 were projected to exceed $10,000 per fill annually for patients enrolled in Medicare Part D plans. Read More ›
